Pfizer's oncology segment does its best to make up for ongoing patent expirations in previously key drugs.
Sean Williams, The Motley Fool, The Motley Fool
Tue, 10/29/2013 - 9:26am
Pfizer's oncology segment does its best to make up for ongoing patent expirations in previously key drugs.